Cell and virus banking in OV development and manufacturing

Mastering oncolytic virus manufacturing 

There are multiple critical aspects of establishing cell and virus banks for the production of oncolytic viruses (OVs). OVs are a promising tool in cancer treatment due to their ability to specifically infect and lyse cancer cells while leaving normal cells unharmed, which has the advantage of avoiding side effects in patients.

Meticulous planning and execution of efficient and robust processes are essential to overcome challenges in the production of OVs and for the commercial viability of OV therapies.
 

The potential of OV therapies

OVs have shown promising potential in cancer treatment due to their tumour cell selectivity and their ability to stimulate the immune system. Even though OVs are currently in the clinical trial phase, positive results present them as a non-invasive treatment option with fewer associated side effects compared to conventional methods, such as surgery or radiation.
 

Challenges and solutions in OV production

Developing and manufacturing OVs poses unique challenges, and establishing cell and virus banks requires careful planning. There are multiple key considerations when starting an OV program:

• Determining parameters and bank size 
  This involves setting crucial parameters for cell and virus banks, considering aspects such as substrate source, clonality, projected future use and recovery after freeze-thaw cycles.
• Performing pre-GMP feasibility studies 
  It is essential to conduct non-GMP verification runs or simulations to ensure the acceptability of cell expansion, viability and productivity for GMP production, thereby reducing risks in the process.
• Ensuring cell and virus bank compliance
  Adhering to strict regulatory requirements for testing production banks is vital. This includes investigating identity, microbial safety, virus safety and genetic stability.
• Amplifying virus seed material 
  If insufficient material is initially produced, further amplification steps should be implemented. These ensure the availability of infectious titers for batch infection.
• Establishing long-term storage conditions 
  The use of suitable containment for OV therapies is essential, alongside any additional needs for storage, testing material and stability studies.

The power of partnerships 

Partnering with an expert contract development and manufacturing organisation (CDMO) offers a strategic advantage in navigating the complexities of establishing cell and virus banks. An experienced CDMO streamlines the process, from determining crucial parameters and conducting pre-GMP feasibility studies to comprehensive characterisation and amplification of virus seed material. 

Collaborating with a CDMO ensures access to state-of-the-art facilities, cutting-edge technologies and a team proficient in optimising storage conditions, ensuring the long-term stability and quality of cell and virus banks. 

A partnership with an oncolytic CDMO not only accelerates the development and manufacturing timeline but also ensures the production of consistent, high-quality OV therapies, enabling a smoother journey from development to commercialisation.

Fill out the form below to access the white paper.